DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.
Ovarian cancer is a highly aggressive and deadly disease. Currently, the treatment for ovarian cancer entails cytoreductive surgery followed by chemotherapy, mainly cisplatin or carboplatin combined with paclitaxel. Although this regimen is initially effective in a high percentage of cases, unfortunately, after few months of initial treatment, tumor relapse occurs due to platinum-resistance. DOXIL (liposomal preparation of doxorubicin) is a choice of drug for recurrent ovarian cancer. However, its response rate is very low and is accompanied by myocardial toxicity. Resistance to chemotherapy and recurrence of cancer is primarily attributed to the presence of cancer stem cells (CSCs), a small population of cells present in cancer. Effect of DOXIL and withaferin A (WFA), both alone and in combination, was investigated on cell proliferation of ovarian cancer cell line A2780 and tumor growth in SCID mice bearing i.p. ovarian tumors. ALDH1 cells were isolated from A2780 using cell sorter, and effect of DOXIL and WFA both alone and in combination on tumorigenic function of ALDH1 was studied using spheroids formation assays in vitro. Western blots were performed to examine the expression of ALDH1 and Notch 1 genes. In our studies, we showed, for the first time, that DOXIL when combined with withaferin A (WFA) elicits synergistic effect on inhibition of cell proliferation of ovarian cancer cells and inhibits the expression of ALDH1 protein, a marker for ALDH1 positive cancer stem cells (CSCs), and Notch1, a signaling pathway gene required for self-renewal of CSCs. Inhibition of expression of both ALDH1 and Notch1 genes by WFA was found to be dose dependent, whereas DOXIL (200 nM) was found to be ineffective. SCID mice, bearing i.p. ovarian tumors, were treated with a small dose of DOXIL (2 mg/kg) in combination with a sub-optimal dose of WFA (2 mg/kg) which resulted in a highly significant (60% to 70%) reduction in tumor growth, and complete inhibition of metastasis compared to control. In contrast, WFA treatment showed a significant reduction in tumor growth but no change in metastasis compared to control. DOXIL showed non-significant reduction in tumor growth and no change in metastasis compared to control. Isolated ALDH1 positive CSCs treated with the combination of DOXIL and WFA resulted in a significant reduction in spheroids formation (tumorigenic function of CSCs) and expression of ALDH1 protein. WFA when used alone at a concentration of 1.5 μM was found to be highly effective in suppression of ALDH1 expression, whereas DOXIL at a concentration of 200 nM was found to be ineffective. DOXIL in combination with WFA elicits synergistic effects, targets cancer stem cells, and has potential to minimize induction of drug resistance and reoccurrence of cancer. Based on our studies, we conclude that the combination of DOXIL with WFA has the potential to be an effective therapy for ovarian cancer and may ameliorate DOXIL related side effects as well as recurrence of ovarian cancer leading to increase in patients' survival rate.
Department of Physiology, University of Louisville, Louisville, KY 40202; James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202.
Sham S
SS
Kakar
James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202.
Christopher A
CA
Worth
Department of Pathology, University of Louisville, Louisville, KY 40202.
Zhenglong
Z
Wang
Department of Physiology, University of Louisville, Louisville, KY 40202.
Kelsey
K
Carter
James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202; Department of Medicine, University of Louisville, Louisville, KY 40202.
Mariusz
M
Ratajczak
James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202.
Pranesh
P
Gunjal
ALDH1; DOXIL; cancer stem cells; combination therapy; ovarian cancer; withaferin A
J Clin Oncol. 2001 Jul 15;19(14):3312-22
11454878
Gynecol Oncol. 2010 Mar;116(3):312-6
19887304
Anticancer Res. 2006 Nov-Dec;26(6C):4943-8
17214367
Vascul Pharmacol. 2006 Jun;44(6):406-10
16713367
Expert Opin Investig Drugs. 2010 Nov;19(11):1339-54
20815774
Breast Cancer Res. 2004;6(6):R605-15
15535842
Stem Cells. 2009 Oct;27(10):2405-13
19658191
Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24
12781368
Cancer Res. 1987 Jan 15;47(2):414-8
3539322
World J Clin Oncol. 2012 Mar 10;3(3):32-42
22442756
Cancer Res. 1992 Jul 15;52(14):3857-64
1617660
J Neurooncol. 1993 Aug;17(2):123-9
8145055
Oncogene. 2010 May 6;29(18):2672-80
20190812
Cancer Res. 2006 Jun 15;66(12 ):6063-71
16778178
PLoS One. 2012;7(7):e42265
22860102
BMC Cancer. 2015 Jul 07;15:502
26148881
PLoS One. 2012;7(1):e29079
22272227
Biosci Rep. 2011 Dec;31(6):449-55
21919891
Cancer Res. 2008 Jun 1;68(11):4311-20
18519691
Ann Oncol. 2005 Feb;16(2):300-6
15668288
Cancer Invest. 2004;22(5):663-9
15581046
Gynecol Oncol. 2003 Sep;90(3):610-8
13678734
Cancer Res. 1988 Jun 15;48(12):3355-9
2897238
PLoS One. 2014 Sep 29;9(9):e107596
25264898
PLoS One. 2012;7(10):e46858
23056490
Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11
16716797
Gynecol Oncol. 2005 Aug;98(2):267-73
15975643
Apoptosis. 2008 Dec;13(12):1494-504
19002588
J Inorg Biochem. 2002 Apr 28;89(3-4):197-202
12062123
Biochem Pharmacol. 1988 Dec 15;37(24):4597-600
3144285
Mol Cell Biochem. 2004 May;260(1-2):39-47
15228084
Int J Gynecol Cancer. 2009 Aug;19(6):1137-41
19820382
BMC Cancer. 2015 May 21;15:423
25994543
Neoplasia. 2015 Aug;17(8):661-70
26408258
Clin Cancer Res. 2012 Feb 1;18(3):869-81
22142828
Clin Cancer Res. 2001 Oct;7(10):2984-97
11595686
Cancer Res. 1988 Jan 1;48(1):68-73
3335000
Biochem Pharmacol. 1994 Feb 11;47(4):689-97
8129746
Gynecol Oncol. 2003 Aug;90(2):390-6
12893206
J Drug Deliv. 2013;2013:898146
23577259
Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8
14656271
Br J Cancer. 2014 Aug 12;111(4):651-9
25025963
J Stem Cells. 2013;8(3-4):189-231
24699025
Arzneimittelforschung. 1973 Jul;23(7):932-5
4147953
Br J Cancer. 2003 Oct 6;89(7):1180-4
14520442
Nature. 1982 Jan 14;295(5845):116-9
6173755
Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6
16716798
J Biol Chem. 1993 Feb 5;268(4):2649-54
8428941
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
25559415
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):65-70
16445612
EJC Suppl. 2014 Dec;12(2):17-20
26759528
J Clin Oncol. 2000 Dec 1;18(23):3936-45
11099323
Nature. 2005 Apr 14;434(7035):843-50
15829953
Clin Exp Metastasis. 2012 Dec;29(8):939-48
22610780
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9
16849428
Clin Breast Cancer. 2013 Feb;13(1):7-15
23127340
Gynecol Oncol. 2007 Dec;107(3):518-25
17910981
Diagn Pathol. 2012 Apr 19;7:44
22515642
Mol Cancer Ther. 2010 Dec;9(12):3186-99
20889728
Angiogenesis. 2004;7(2):115-22
15516832
Cell Cycle. 2009 Jan 1;8(1):158-66
19158483
J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):41-52
16947085
Ann Oncol. 2007 Feb;18(2):263-8
17108151
Gynecol Oncol. 2006 Feb;100(2):318-23
16239023
Cancer Res. 2005 Apr 15;65(8):3025-9
15833827
J Cancer. 2014 Mar 16;5(5):301-10
24723972
Mol Cancer. 2013 Mar 27;12:24
23537295
Ann Oncol. 2015 Oct;26(10 ):2141-9
26216383